The Latin America, Middle East and Africa Anti-Obesity Drugs Market should witness market growth of 14.9% CAGR during the forecast period (2023-2029).
Prescription drugs can aid in weight loss and maintenance for certain people when accompanied by behavioral modifications like healthier eating and increased exercise. People who use prescription drugs in conjunction with a lifestyle program typically lose more of their beginning body weight after a year than those who do not use prescription drugs. Some persons who use prescription weight-management drugs see a weight loss of 10% or more compared to their beginning weight. By lowering blood pressure, blood sugar, and lipid levels, weight loss of 5% to 10% of the initial body weight may assist the person's health. Additionally, certain additional health issues linked to being overweight or obese, like joint pain and sleep apnea, can be improved by losing weight. Within the first six months of using the medicine, most weight loss occurs.
The estimated range of diabetes prevalence in Saudi Arabia was between 9% and 22% from 1980 to 2008. It is estimated that there are approximately 7 million individuals with diabetes and an additional 3 million in the prediabetic phase. The prevalence of this region is being impacted by various factors, including unhealthy lifestyles, genetic susceptibility, and an increase in the incidence of type 2 diabetes mellitus among young adults and children. The rise in diabetes is anticipated to boost the utilization of anti-obesity drugs as they are efficient in countering diabetic illness, especially in people who are also suffering from obesity, increasing the market growth in the region.
The Brazil market dominated the LAMEA Anti-Obesity Drugs Market by Country in 2022, and would continue to be a dominant market till 2029; thereby, achieving a market value of $64.5 million by 2029. The Argentina market is experiencing a CAGR of 15.5% during (2023-2029). Additionally, The UAE market would display a CAGR of 14.6% during (2023-2029).
Based on Drug Type, the market is segmented into Prescription Drugs and Over The Counter Drugs. Based on Mechanism of Action, the market is segmented into Centrally Acting and Peripherally Acting. Based on Route Of Administration, the market is segmented into Oral Route and Subcutaneous Route. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Pfizer, Inc., Boehringer Ingelheim International GmbH, GlaxoSmithKline PLC, Novo Nordisk A/S, Rhythm Pharmaceuticals, Inc., Gelesis Holdings Inc. (PureTech Health), Currax Pharmaceuticals LLC (Currax Holdings USA LLC), Vivus LLC, CHEPLAPHARM Arzneimittel GmbH (Braun Beteiligungs GmbH) and KVK Tech, Inc.
Prescription drugs can aid in weight loss and maintenance for certain people when accompanied by behavioral modifications like healthier eating and increased exercise. People who use prescription drugs in conjunction with a lifestyle program typically lose more of their beginning body weight after a year than those who do not use prescription drugs. Some persons who use prescription weight-management drugs see a weight loss of 10% or more compared to their beginning weight. By lowering blood pressure, blood sugar, and lipid levels, weight loss of 5% to 10% of the initial body weight may assist the person's health. Additionally, certain additional health issues linked to being overweight or obese, like joint pain and sleep apnea, can be improved by losing weight. Within the first six months of using the medicine, most weight loss occurs.
The estimated range of diabetes prevalence in Saudi Arabia was between 9% and 22% from 1980 to 2008. It is estimated that there are approximately 7 million individuals with diabetes and an additional 3 million in the prediabetic phase. The prevalence of this region is being impacted by various factors, including unhealthy lifestyles, genetic susceptibility, and an increase in the incidence of type 2 diabetes mellitus among young adults and children. The rise in diabetes is anticipated to boost the utilization of anti-obesity drugs as they are efficient in countering diabetic illness, especially in people who are also suffering from obesity, increasing the market growth in the region.
The Brazil market dominated the LAMEA Anti-Obesity Drugs Market by Country in 2022, and would continue to be a dominant market till 2029; thereby, achieving a market value of $64.5 million by 2029. The Argentina market is experiencing a CAGR of 15.5% during (2023-2029). Additionally, The UAE market would display a CAGR of 14.6% during (2023-2029).
Based on Drug Type, the market is segmented into Prescription Drugs and Over The Counter Drugs. Based on Mechanism of Action, the market is segmented into Centrally Acting and Peripherally Acting. Based on Route Of Administration, the market is segmented into Oral Route and Subcutaneous Route. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Pfizer, Inc., Boehringer Ingelheim International GmbH, GlaxoSmithKline PLC, Novo Nordisk A/S, Rhythm Pharmaceuticals, Inc., Gelesis Holdings Inc. (PureTech Health), Currax Pharmaceuticals LLC (Currax Holdings USA LLC), Vivus LLC, CHEPLAPHARM Arzneimittel GmbH (Braun Beteiligungs GmbH) and KVK Tech, Inc.
Scope of the Study
By Drug Type
- Prescription Drugs
- Over The Counter Drugs
By Mechanism of Action
- Centrally Acting
- Peripherally Acting
By Route Of Administration
- Oral Route
- Subcutaneous Route
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Country
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- Pfizer, Inc.
- Boehringer Ingelheim International GmbH
- GlaxoSmithKline PLC
- Novo Nordisk A/S
- Rhythm Pharmaceuticals, Inc.
- Gelesis Holdings Inc. (PureTech Health)
- Currax Pharmaceuticals LLC (Currax Holdings USA LLC)
- Vivus LLC
- CHEPLAPHARM Arzneimittel GmbH (Braun Beteiligungs GmbH)
- KVK Tech, Inc.
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. LAMEA Anti-Obesity Drugs Market by Drug Type
Chapter 4. LAMEA Anti-Obesity Drugs Market by Mechanism of Action
Chapter 5. LAMEA Anti-Obesity Drugs Market by Route Of Administration
Chapter 6. LAMEA Anti-Obesity Drugs Market by Distribution Channel
Chapter 7. LAMEA Anti-Obesity Drugs Market by Country
Chapter 8. Company Profiles
Companies Mentioned
- Pfizer, Inc.
- Boehringer Ingelheim International GmbH
- GlaxoSmithKline PLC
- Novo Nordisk A/S
- Rhythm Pharmaceuticals, Inc.
- Gelesis Holdings Inc. (PureTech Health)
- Currax Pharmaceuticals LLC (Currax Holdings USA LLC)
- Vivus LLC
- CHEPLAPHARM Arzneimittel GmbH (Braun Beteiligungs GmbH)
- KVK Tech, Inc.
Methodology
LOADING...
